Aptevo Therapeutics Inc (APVO) is a publicly traded Healthcare sector company. As of May 21, 2026, APVO trades at $4.57 with a market cap of $5.47M and a P/E ratio of -0.05. APVO moved +0.00% today. Year to date, APVO is -45.25%; over the trailing twelve months it is -95.92%. Its 52-week range spans $3.80 to $6,859.80. Analyst consensus is buy with an average price target of $21.00. Rallies surfaces APVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aptevo reports 87% clinical benefit in frontline AML trial; $60M credit line extends runway: Mipletamig achieved an 87% clinical benefit rate and 81% CR/CRi in 31 frontline AML patients, with 65% complete remission and no cytokine release syndrome. Aptevo raised a $60 million equity credit line to extend capital through 2029 and installed Jeff Lamothe as CEO with Marvin White as Executive Chair.
| Metric | Value |
|---|---|
| Price | $4.57 |
| Market Cap | $5.47M |
| P/E Ratio | -0.05 |
| EPS | $-87.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $6,859.80 |
| 52-Week Low | $3.80 |
| Volume | 417 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-25.97M |
| Gross Margin | 0.00% |
1 analysts cover APVO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.00.